UNSPSC 51144702: Nikethamide

This classification denotes a cns stimulant with the molecular formula C10H14N2O, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier (SRS UNII) 368IVD6M32, chemically known as 3-pyridinecarboxamide, n,n-diethyl- but more generally known as nikethamide, which bears US NIH Compound Identifier 5497. European Medicines Agency schedules Nikethamide in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09286MIG. The term NIKETHAMIDE is an International Non-Proprietary Name.

UNSPSC 51144702 Nikethamide is a Commodity-tier code that in practice does not align with recent state and local procurement activity. The code nominally describes a specific pharmaceutical stimulant, yet the three most recent opportunities posted under or near this code — Seminole County's procurement of naloxone and drug deactivation systems, Texas HHS's RFI on direct-to-manufacturer prescription programs, and MMCAP's RFP for generic multi-source pharmaceuticals and OTC products — cover naloxone (an opioid antagonist), prescription fulfillment platforms, and broad-spectrum generic pharmaceuticals and over-the-counter products respectively. None of these solicitations target nikethamide specifically or any single-molecule pharmaceutical agent. The mismatch between the code's nominal scope and what state and local governments are actually buying under it suggests either a classification error in the source data or that this code does not reflect genuine procurement activity at the state and local level.

The issuing bodies span a county health department, a state HHS commission, and a multistate cooperative purchasing alliance (MMCAP), indicating activity across health and human services channels. Geographic presence appears limited to Florida, Texas, and the MMCAP member states (Minnesota and Oregon among those named). Representative recent opportunities include Seminole County's IFB for naloxone and drug deactivation systems (due July 26, 2023), Texas HHS's RFI on direct prescription programs (due April 3, 2026), and MMCAP's RFP for generic pharmaceuticals (due March 26, 2026). The absence of consistent nikethamide-specific procurement activity and the structural mismatch between code definition and actual solicitation scope suggest limited decision relevance for vendors targeting this commodity code.